Publications by authors named "Michele C Azada"

Claim this Profile
A
Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
Sai-Hong Ignatius Ou, Michael Weitz, John R Jalas, Daniel F Kelly, Vanessa Wong, Michele C Azada

Lung Cancer· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
Sai-Hong Ou, Jeffrey C Milliken, Michele C Azada, Vincent A Miller, Siraj M Ali

Lung Cancer· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.
Sai-Hong Ignatius Ou, Zachary R Chalmers, Michele C Azada, Jeffrey S Ross, Philip J Stephens

Lung Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.
Sai-Hong Ignatius Ou, Samuel J Klempner, Michele C Azada, Veronica Rausei-Mills, Christopher Duma

Lung Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Sai-Hong Ignatius Ou, Joel Greenbowe, Ziad U Khan, Michele C Azada, Jeffrey S Ross

Lung Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
Stephanie Lu, Michele C Azada, Sai-Hong Ignatius Ou

Lung Cancer· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.
Sai-Hong Ignatius Ou, Karen R Sommers, Michele C Azada, Edward B Garon

Oncologist· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Shirish M Gadgeel, Leena Gandhi, Gregory J Riely, Alberto A Chiappori, Howard L West, Michele C Azada

Lancet Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis